Diagnostic challenges in an aggressive case of peripheralizing marginal zone lymphoma

Sujal I. Shah, Christopher R. D’Angelo, Jeremy D. Kratz, David T. Yang

CASE REPORT

INTRODUCTION

Evaluation of B-cell lymphomas benefits from cytogenetic analysis, however, limitations in conventional karyotyping and fluorescence in situ hybridization curtail their clinical utility. This case highlights value of cytogenetics in diagnosis of atypical B-cell lymphoma and discusses the benefits of new technology that can overcome the limitations of conventional cytogenetic studies.

Mature B-cell neoplasms are relatively common neoplasms that can occasionally pose diagnostic challenges. In these cases, cytogenetics can be a useful tool for both diagnosis and prognosis. Common ancillary cytogenetics studies—conventional karyotyping and fluorescence in situ hybridization (FISH)—are almost universally available; however, both modalities have limitations that can curtail their utility in evaluation of mature B-cell neoplasms with atypical presentation or phenotypes. We present a case of peripheralizing marginal zone lymphoma with an atypical immunophenotype and clinical presentation and discuss the advantages and limitations of both conventional karyotyping and FISH in this setting. We also discuss how next-generation sequencing (NGS) based methods, specifically referencing mate-pair sequencing (MPSeq) can bridge the gap between these limitations and why they should be considered in the toolkit of ancillary cytogenetic tests.

CASE PRESENTATION

A 68-year-old Caucasian man with a past medical history of obstructive sleep apnea, hypertension, and gout presented to a community hospital with shortness of breath, night sweats, and fatigue. His dyspnea had significantly worsened, in
addition to experiencing a 38 lb. weight loss over the prior 3 months. Physical examination revealed splenomegaly and lower extremity edema without lymphadenopathy. Blood work revealed a markedly elevated WBC count of 423 K/μL, along with hyperkalemia (7.2 mmol/L), hypercalcemia (11.8 mg/dL), elevated liver enzymes (ALT 55 U/L, AST 91 U/L, alkaline phosphatase 236 U/L), lactic acidosis (5.0 mmol/L), and elevated creatinine (1.47 mg/dL). He was transferred for further workup and care.

The initial presenting symptoms, laboratories, and physical examination findings in this patient raised concern for a hematologic malignancy with spontaneous tumor lysis syndrome. Given the markedly elevated peripheral WBC count, the initial differential diagnosis list included acute leukemia, chronic leukemia, and peripheralizing lymphoma. (Causes of neoplastic leukocytosis are listed in Table 1.) Initial examination of the peripheral smear was concerning for atypical lymphocytes versus possible blasts, with cells showing large round nuclei and scant cytoplasm (Figure 1). Bilobed nuclei or Auer rods were not appreciated.

The patient had no known history of underlying kidney disease, with baseline creatinine of 1.0 mg/dL. Given his elevated creatinine at presentation, along with the additional metabolic derangements of hyperkalemia, hypercalcemia, and lactic acidosis, the initial working diagnosis was tumor lysis syndrome with acute kidney injury.

Hematopathology review of the peripheral smear revealed a predominance of intermediate-sized lymphoid cells with scant cytoplasm, smooth nuclear contours, and condensed nuclear chromatin comprising 92% of the nucleated cells. No Auer rods or cytoplasmic granules were seen. With these findings, chronic leukemia or peripheralizing lymphoma were considered the most likely underlying malignancy, with acute leukemia considered less likely based on morphologic assessment of the leukocytosis. (Common neoplastic causes of marked lymphocytosis are listed in Table 2.)

The morphology of the circulating atypical lymphocytes was not classic for chronic lymphocytic leukemia (CLL) or B-cell prolymphocytic leukemia, heightening the concern for T-cell prolymphocytic leukemia or a peripheralizing lymphoma.

### 2.1 Investigations

Flow cytometry studies revealed the circulating lymphocytes were clonal B cells that expressed CD45, bright CD20, CD19, CD5, and bright lambda light chains without CD10, CD23, CD200, or CD38 (Figure 2). The flow was interpreted as a CD5-positive B-cell lymphoproliferative disorder, favoring mantle cell lymphoma, as the immunophenotype was not characteristic for CLL.

Of the CD5-positive B-cell leukemias, CLL and peripheralizing mantle cell lymphoma are the most common, though occasionally marginal zone lymphomas and follicular lymphomas also can express CD51,2 (Table 3). The additional findings on flow cytometry in this case (CD23-negative, CD200-negative, bright immunoglobulin, and bright CD20 expression) are not characteristic of CLL, bringing mantle cell lymphoma to the top of the differential list, with an atypical CLL less likely. Fluorescence in situ hybridization (FISH) studies for t(11;14) CCND1/IGH fusion were ordered for confirmation, with suggestion to also perform a CLL FISH panel should CCND1/IGH fusion be negative.

Peripheralizing mantle cell lymphoma is frequently a result of an aggressive leukemic transformation of the underlying disease, which in this case fits with the clinical presentation of tumor lysis syndrome. However, leukemic transformation on mantle cell lymphoma should be associated with diffuse lymphadenopathy. In this case, staging CT scans of the chest, abdomen, and pelvis confirmed the physical examination findings of splenomegaly, measuring up to 21 cm in the intracranial coronal dimension, with peripheral wedge-shaped infarcts, but no frank adenopathy was noted (Figure 3). Alternatively, an indolent subtype of mantle cell lymphoma has been identified that typically presents with isolated circulating disease without lymphadenopathy, but as the name suggests, patients tend to be asymptomatic and have minimal lymphocytosis.3,4

To evaluate further, a bone marrow aspirate and core biopsy were performed. The bone marrow aspirate showed increased numbers of small mature lymphocytes without an increase in plasma cells or plasmacytoid lymphocytes. The biopsy showed increased numbers of small lymphocytes both in an infiltrative pattern and forming loose lymphoid aggregates, occupying approximately 20% of the marrow space. Immunohistochemical staining showed the lymphocytes expressed CD20 and PAX5. No areas concerning for large cell transformation were identified.

Given the suspicion for mantle cell lymphoma, Cyclin D1 stain was performed—and came back negative. A small proportion of mantle cell lymphoma cases are known to be

### TABLE 1 Common Neoplastic Causes of Leukocytosis

| Common Neoplastic Causes Leukocytosis       | Predominant Cell Type              |
|--------------------------------------------|-----------------------------------|
| Chronic lymphocytic leukemia               | Mature lymphocytes                |
| Chronic myeloid leukemia                   | Bands and segmented neutrophils   |
| Acute lymphoblastic lymphoma               | Lymphoid blasts                   |
| Acute myeloid leukemia                     | Myeloid blasts (& blast-equivalents) |
Cyclin D1 negative, therefore SOX11 staining was subsequently performed—and was also negative. Immunostain for p53 was initially ordered given the leading differential of mantle cell lymphoma and was also negative. These results, while not completely excluding mantle cell lymphoma, made the diagnosis highly unlikely. Likewise, CLL also remained unlikely based on the previous flow cytometry results, as well as a lack of CD23 or LEF1 expression as evaluated by immunohistochemistry on the core biopsy specimen (Figure 4).

While considering this diagnostic dilemma, karyotyping results performed on the bone marrow aspirate became available. Conventional karyotyping revealed an abnormal clone with highly complex structural and numerical abnormalities, comprising 16 out of 20 metaphase cells. Some of the abnormalities identified included t(2;7) and t(1;12), along with del(9p), del(13q), loss of Y, iso(8q) and iso(17q). Of note, t(11;14) CCND1/IGH was not identified and FISH for t(11;14) was also negative, further confirming that the neoplastic process was not mantle cell lymphoma. Review of published literature revealed a few case reports and case series of t(2;7)(p11.2;q22) being associated with marginal zone lymphoma, including splenic marginal zone lymphoma. While marginal zone lymphoma typically does not express CD5, expression has been identified in up to 25% of cases.

Not only were the karyotyping results helpful in establishing the diagnosis of marginal zone lymphoma, they also were prognostically significant. Isochromosome 17q results in deletion of one TP53 allele on the short arm of chromosome 17 and mutation analysis, ordered on peripheral blood when the diagnosis of mantle cell lymphoma was being entertained, revealed that the remaining TP53 allele showed a likely pathogenic truncating mutation: p.Glu258Thrfs*86. The presence of biallelic TP53 derangement likely contributed to the complex karyotype and aggressive clinical presentation of this B-cell lymphoma. Interestingly, truncating TP53 mutations are associated with lack of p53 immunohistochemical staining, as demonstrated in this case.

Overall, the constellation of clinical, immunophenotypic, molecular, and cytogenetic findings in this challenging case, resulted in a final diagnosis of CD5-positive B-cell lymphoproliferative disorder with t(2;7)(p11.2;q22) and TP53 mutation, favoring splenic marginal zone lymphoma.

### Treatment

The patient received intravenous fluids, allopurinol, and rasburicase for treatment of tumor lysis syndrome with improvements in his electrolyte derangements and creatinine. Based on the working diagnosis of B-cell lymphoma, he received an empiric course of steroids while awaiting formal diagnosis for definitive treatment. Additionally, based on this working diagnosis, the patient was treated with a single cycle of bendamustine and rituximab chemoimmunotherapy. This resulted in a transient improvement in his peripheral lymphocytosis, but was also complicated by a severe desquamating skin rash diagnosed as Stevens-Johnson syndrome. He recovered and, based on the poor prognosis associated with TP53 mutated B-cell lymphomas, went on to receive combination therapy.
venetoclax and obinutuzumab, which resulted in complete resolution of his peripheral lymphocytosis after 1 cycle. He has since continued on treatment with venetoclax and obinutuzumab and is now approximately 3 months out from his initial diagnosis.

3 | DISCUSSION

This case illustrates the benefit of additional ancillary testing in diagnosing a peripheralizing lymphoma in an acutely ill patient that was not definitively classifiable based on flow cytometry, bone marrow histology, and immunohistochemistry. Peripheral blood revealed a marked lymphocytosis, comprised of small, mature lymphocytes. Flow cytometry revealed an atypical, CD5-positive population of monoclonal B-lymphocytes; however, additional markers and subsequent immunohistochemical stains performed on the bone marrow biopsy were not in keeping with a diagnosis of either chronic lymphocytic leukemia or mantle cell lymphoma.

It was fortunate that evaluable neoplastic cells in metaphase could be obtained from a bone marrow aspirate for conventional karyotyping, which revealed a complex karyotype that included a t(2;7) translocation, an anomaly that has been associated with marginal zone lymphoma including a few cases of splenic marginal zone lymphoma. In conjunction with the clinical findings of splenomegaly without significant adenopathy, peripheralizing splenic marginal zone lymphoma was favored as the final diagnosis. In addition,
isochromosome (17q) found on karyotyping combined with TP53 mutation detected by next-generation sequencing confirmed a biallelic TP53 derangement, likely contributing to the patient's aggressive presentation. These ancillary studies proved invaluable in reaching a final diagnosis and risk-stratification in this case.

In mature B-cell neoplasms, cytogenetic analysis can be a useful tool for both diagnosis and prognosis. This case highlights the advantage of the unbiased nature of conventional karyotyping over FISH, where it was very unlikely that FISH analysis for t(2;7) would have been pursued. However, conventional karyotyping requires isolation of mitotically active,
dividing cells, which are difficult to grow in vitro in low-grade lymphomas and as a result, is typically non-contributory in lymphoma diagnosis. In addition, the resolution of conventional karyotyping is approximately 5-10 Mb, with smaller insertions/deletions/translocations remaining ‘cytogenetically cryptic’ by conventional karyotype. In contrast, FISH does not require presence of living, dividing cells and has a resolution of approximately 100 Kb. The limitation of FISH is that it is a targeted methodology, where specific probes must be selected to detect specific insertion, deletion, or translocations that are suspected.

Newer ancillary studies are now available that can bridge the gap between the limitations of conventional karyotyping and FISH. An example is mate-pair sequencing (MPseq), which utilizes next-generation sequencing technology to provide unbiased, relatively high-resolution DNA analysis for insertions, deletions, and translocations. Mate-pair sequencing involves the formation of libraries, which are produced by initially generating kilobase-sized fragments. Markers are added to the ends of these fragments, and the fragments are circularized and ligated. Non-circularized DNA molecules are removed with exonucleases, and the residual, circularized molecules are sheared into small, approximately 500bp fragments (Figure 5). The library of fragments, purified using magnetic beads, is assessed by paired-end next-generation sequencing. The resulting 100-150 base pairs of sequence generated from these two end fragments can then be aligned to a reference genome. The mate-pairs provide information about the entire region between the two fragments, known as bridged coverage. As a result, MPseq can be used to detect rearrangements genome-wide, both balanced and unbalanced structural and copy-number abnormalities, with significantly greater resolution and sensitivity than conventional karyotype without the need for mitotically active cells.

FIGURE 5  Mate-pair sequencing. 1) Genomic DNA is fragmented to 2-5 Kb fragments and 2) the ends of the fragments are biotinylated. 3) Fragments are then circularized to bring the biotinylated ends together and then 4) the circularized DNA is fragmented to 200-500 bp fragments. 5) Biotinylated fragments are captured and 6) the library preparation is completed by adding tags and adaptor sequences to the fragment ends for identification during multiplexing and hybridizing to the flow cell for subsequent 7) cluster generation. Because the fragment was originally circularized, the sequence obtained should be mapped to two areas of the genome approximately 2-5 Kb apart. A genomic duplication or deletion will result in an unexpected distance between the sequences on a fragment. A translocation will result in the mapping of two unexpected chromosomes on the same fragment. An inversion will result in mapping an unexpected orientation in a portion of the sequence of a fragment.
Additionally, MPseq allows for comprehensive evaluation using a single assay, as opposed to large panels of independent FISH probes.22

4 | CONCLUSION

Cytogenetic studies are a useful tool in instances where mature B-cell neoplasms prove to be diagnostically challenging, with the results providing both diagnostic and prognostic benefit. To this end, conventional karyotyping and fluorescence in situ hybridization (FISH) are almost universally available; however, both methodologies have limitations that can impede on their utility in evaluation of low-grade and mature B-cell neoplasms. Newer testing methodologies, such as MPseq, provide opportunities to work around these limitations.

While we were fortunate that conventional karyotyping was successful in this case, it helps to highlight the benefits of employing these new technologies to aid not only in the diagnosis of challenging cases, but also possibly in more comprehensively characterizing the chromosomal anomalies of otherwise seemingly routine cases.22,23

ACKNOWLEDGEMENTS

The authors would like to acknowledge the patient and his family for their contributions to this report. Published with written consent of the patient.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

SS performed the literature search and drafted the initial manuscript. CD provided the treatment section for the manuscript. SS and JK provided pathologic and clinical images, respectively. DY and SS were involved in the pathologic diagnosis of the case. CD and JK were involved in the clinical care of the patient. CD and DY critically revised the manuscript. All authors read and approved the final manuscript and agree to be fully accountable for ensuring the integrity and accuracy of the work.

ETHICAL STANDARDS

Informed consent was obtained from the patient discussed in this report. Our institution does not require ethical approval for case reports.

ORCID

Sujal I. Shah https://orcid.org/0000-0002-0125-1448

REFERENCES

1. Baseggio L, Traverse-Glehen A, Petinataud F, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinicopathological, cytogentic and molecular study of 24 cases. Haematologica. 2010;95(4):604-612.
2. Li Y, Hu S, Zuo Z, et al. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015;28(6):787-798.
3. Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96(8):1121-1127.
4. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307-5316.
5. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1--negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315-4321.
6. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555-1562.
7. Wotherspoon AC. Extranodal and splenic small B-cell lymphoma. Mod Pathol. 2013;1:1-S29-41.
8. Hayette S, Tigaud I, Callet-Bauchu E, et al. In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood. 2003;102(4):1549-1550.
9. Brito-Babapulle V, Gruszka-Westwood AM, Platt G, et al. Translocation t(2;7)(p12;q21–22) with dysregulation of the CDK6 gene mapping to 7q21–22 in a non-Hodgkin's lymphoma with leukemia. Haematologica. 2002;87:357-362.
10. Douet-Guilbert N, Tous C, Le Flahé G, et al. Translocation t(2;7)(p12;q21) associated with the CDK6/IGK rearrangement is a rare but recurrent abnormality in B-cell lymphoproliferative malignancies. Cancer Genet. 2014;207(3):83-86.
11. Corcoran MM, Mould SJ, Orchard JA, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18(46):6271-6277.
12. Huret JL. t(2;7)(p11;q21) - t(7;14)(q21;q32) CDK6/IGH - t(7;22)(q21;q11). Atlas Genet Cytogenet Oncol Haematol. 2010;14(1):68-69.
13. Kojima M, Sato E, Oshimi K, et al. Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation; clinical, flow cytometry, and histopathological findings of 11 cases. J Clin Exp Hematop. 2010;50:107-112.
14. Giannouli S, Paterakis G, Ziakas PD, et al. 7q21 translocations lead to overexpression of the CDK6 gene. Haematologica. 2009;94(11):1555-1562.
15. Murnyák B, Hortobágyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. 2016;7(40):64910-64920.
16. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemotherapy. Blood. 2017;130(17):1903-1910.
17. Cook JR, Shekhter-Levin S, Swerdlow SH. Utility of routine classical cytogenetic studies in the evaluation of suspected lymphomas: results of 279 consecutive lymph node/extranodal tissue biopsies. Am J Clin Pathol. 2004;121(6):826-835.
18. Bridge JA. Advantages and limitations of cytogenetic, molecular cytogenetic, and molecular diagnostic testing in mesenchymal neoplasms. J Orthop Sci. 2008;13(3):273-282.
19. Gao G, Smith DI. How can mate-pair sequencing be utilized for cancer patients? *Expert Rev Mol Diagn*. 2017;17(1):1-3.
20. Peterson JF, Pitel BA, Smoley SA, et al. Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements. *Cold Spring Harb Mol Case Stud*. 2019;5(3):a004077.
21. Johnson SH, Smoley SA, Kearney HM, et al. A comparison of whole genome mate pair sequencing (MPseq) with karyotype and FISH for breakpoint detection in hematologic cancers. *Cancer Genet*. 2016;209(6):290.
22. Aypar U, Smoley SA, Pitel BA, et al. Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. *Eur J Haematol*. 2019;102(1):87-96.
23. Peterson JF, Pitel BA, Smoley SA, et al. Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. *Hum Pathol*. 2019;89:109-114.
24. Wang HY, Zu Y. Diagnostic algorithm of common mature B-cell lymphomas by immunohistochemistry. *Arch Pathol Lab Med*. 2017;141(9):1236-1246.

How to cite this article: Shah SI, D’Angelo CR, Kratz JD, Yang DT. Diagnostic challenges in an aggressive case of peripheralizing marginal zone lymphoma. *Clin. Case Rep*. 2020;8:3302–3309. [https://doi.org/10.1002/ccr3.3395](https://doi.org/10.1002/ccr3.3395)